Chronic inflammation plays a significant role in many important diseases and conditions, including heart disease, diabetes, rheumatoid arthritis, MS, neurodegenerative diseases, and asthma. Research suggests that an unbalanced gut microbiome can be linked to inflammatory bowel disease, obesity, type 2 diabetes, colon cancer, and depression.
We are a biopharmaceutical company with a suite of compounds that in preclinical studies elicited potent anti-inflammatory activity, activated antioxidant pathways, and showed strong effects in modulating the gut microbiome.
Who We’re Working With
Contact
Investor Inquiries:
Gordon Eberwein
geberwein@derm-biome.com
https://derm-biomepharmaceuticals.com/
https://pan-biomepharmaceuticals.com/